Loading...

Member Profile

Home / Members

Orient PHARMA Co., Ltd.




Chairman
  • Peter Tsai
Date Established
  • 2008/02/01
TWSE Stock ID
  • 4166
Market Valuation
  • USD  80,000,000.0
Phone Number
  • +886-2-2325-7621
Address
  • 12F, No. 128, Sec. 6 Chengde Rd., Taipei 112, Taiwan, R.O.C.
Website Theraputic Fields
  • Cardiology/Vascular Diseases
  • Endocrinology/Metabolic Disorders
  • Neuroscience
  • Psychiatry/ Psychology
Product Classification
  • 505(b)(2)
  • Technology Platform
Awards
  1. OrientPHARMA (2PN012 and 2PN006) Awarded Bronze Medal of 2015 MOHW/MOEA Pharmaceutical Technology Research and Development Award
  2. Orient PHARMA Co., Ltd (Methydur Sustained Release Capsules) awarded the Innovation of the Year of 2019 Taiwan Bio-Industry Organization Awards
  3. Orient PHARMA Co., Ltd (Methydur Sustained Release Capsules 22mg, 33mg, 44mg) awarded Siver Medal of 2020 MOHW/MOEA Pharmaceutical Technology Research and Development Award
Top Products
  1. Pitator
  2. Zulitor
  3. Methydur

OrientPHARMA CO., Ltd.(OP) is the subsidiary company of Orient EuroPharma Co., Ltd., established in 2008. The primary strength is on R&D, clinical trials and manufacturing of new drugs. The plant in Yunlin is a whole new constructed plant which had been certified by Taiwan PIC/S GMP, Japan “Accreditation Certificate of Foreign Drug Manufacturer” and cGMP inspection by US FDA.

OP utilizes its technology platform of Multi-Phasic Release Technology (MPRT), focusing on developing 505 (B) (2) new drugs including new dosage forms, new formulations, new indications and new compounds. OP develops new drugs in line with trends and unmet medical needs, and cooperates with international R&D companies to accelerate the development of new drugs. Its research and development results have obtained multi-national patents. By 2022, it has obtained five US ANDA and 1 TW 505(b)(2) drug certificates . In addition, there are 4 new 505(b)(2) combo products under development. Holding the vision of being a “global professional specialty pharma”, OP continues to use patented technology to develop 505 (b) (2) new drugs and niche generic drugs, and expand production capacity to grow up the international market.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2008 Orient PHARMA Co., Ltd. Established in Feb, 2008.
   2011 OrientPHARMA Received the Domestic PICS GMP Certification
   2012 Listed in Taipei Exchange, stock code: 4166
   2014 OrientPHARMA Signs an Agreement with Actavis for the Introduction of Generic Antihyperlipidemic, Pitavastatin, to the U.S. Market
   2014 OP’S Carisoprodol Tablets USP 350mg, has officially received the license from US FDA
   2015 OP’s Milglitol license was approved by US FDA.
   2017 The Paragraph IV ANDA application of PITAVASTATIN has approved by U.S. FDA.
   2017 Methydur Sustained Release Capsules for treating ADHD showed significant benefits in Phase III trial.
   2019 OP obtained USFDA approval of generic drug for diabetes, Glyburide Tablets USP (1.25 mg, 2.5 mg, 5 mg)
   2019 OP obtained USFDA approval of generic drug for infection, Vancomycin Hydrochloride Capsules USP (125 mg and 250 mg)
   2019 Orient PHARMA Co., Ltd (Methydur Sustained Release Capsules) awarded the Innovation of the Year of 2019 Taiwan Bio-Industry Organization Awards
   2020 Methydur Sustained Release Capsules (Methydur), is the first marketed 505(b)(2) new drug internationally with clinical value in Taiwan, obtained a premium health insurance reimbursement price
   2021 1PC111 product completed clinical Phase III study in Taiwan, Australia and New Zealand and Taiwan 505(b)(2) new drug registration.